sellWeak cluster of 3
Vikas Sinha sold $3,053 of KLRS
See Remarks at Kalaris Therapeutics, Inc.. 303 shares at an average of $10.08, traded Feb 21, 2025, filed Feb 24, 2025.
Warning score
30Value
$3,053
303 shares
Holdings after
49,129
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-025634, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | SOpen-market sale Common Stock | -303 | $10.08 | $3,053 | 49,129 | Feb 24, 2025 |
Related signals
Other insiders at Kalaris Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | KLRSbuy Kalaris Therapeutics, Inc. | Srinivas Akkaraju director, owner | $1.2M 244,300 shares | +12% | |
| 35Weak | KLRSsell Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $13k 1,915 shares | -100% | |
| 46Moderate | KLRSbuy Kalaris Therapeutics, Inc. | Srinivas Akkaraju director, owner | $5.0M 479,847 shares | +32% | |
| 25Weak | KLRSsell Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $8,135 907 shares | -32% | |
| 30Weak | Kalaris Therapeutics, Inc. | Edward Miller General Counsel | $1,068 106 shares | -2% | |
| 30Weak | Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $967 96 shares | -3% | |
| 30Weak | Kalaris Therapeutics, Inc. | Vikas Sinha See Remarks | $1,226 129 shares | -0% | |
| 30Weak | Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $342 36 shares | -1% | |
| 30Weak | Kalaris Therapeutics, Inc. | Edward Miller General Counsel | $494 52 shares | -1% | |
| 30Weak | Kalaris Therapeutics, Inc. | Vikas Sinha See Remarks | $431 979 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.